Guggenheim Reiterates Buy on Enliven Therapeutics, Maintains $78 Price Target
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
Guggenheim analyst Michael Schmidt reiterates Enliven Therapeutics (NASDAQ:ELVN) with a Buy and maintains $78 price target.
Guggenheim analyst Michael Schmidt reiterates Enliven Therapeutics (NASDAQ:ELVN) with a Buy and maintains $78 price target.